These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

217 related items for PubMed ID: 26685859

  • 1. Hearing and tinnitus in head and neck cancer patients after chemoradiotherapy.
    Niemensivu R, Saarilahti K, Ylikoski J, Aarnisalo A, Mäkitie AA.
    Eur Arch Otorhinolaryngol; 2016 Sep; 273(9):2509-14. PubMed ID: 26685859
    [Abstract] [Full Text] [Related]

  • 2. Prediction of Hearing Loss Due to Cisplatin Chemoradiotherapy.
    Theunissen EA, Zuur CL, Józwiak K, Lopez-Yurda M, Hauptmann M, Rasch CR, van der Baan S, de Boer JP, Dreschler WA, Balm AJ.
    JAMA Otolaryngol Head Neck Surg; 2015 Sep; 141(9):810-5. PubMed ID: 26291150
    [Abstract] [Full Text] [Related]

  • 3. A new grading system for ototoxicity in adults.
    Theunissen EA, Dreschler WA, Latenstein MN, Rasch CR, van der Baan S, de Boer JP, Balm AJ, Zuur CL.
    Ann Otol Rhinol Laryngol; 2014 Oct; 123(10):711-8. PubMed ID: 24820112
    [Abstract] [Full Text] [Related]

  • 4. Ototoxic effects of supradose cisplatin with sodium thiosulfate neutralization in patients with head and neck cancer.
    Madasu R, Ruckenstein MJ, Leake F, Steere E, Robbins KT.
    Arch Otolaryngol Head Neck Surg; 1997 Sep; 123(9):978-81. PubMed ID: 9305250
    [Abstract] [Full Text] [Related]

  • 5. Audiometric patterns in ototoxicity of intra-arterial Cisplatin chemoradiation in patients with locally advanced head and neck cancer.
    Zuur CL, Simis YJ, Lansdaal PE, Rasch CR, Tange RA, Balm AJ, Dreschler WA.
    Audiol Neurootol; 2006 Sep; 11(5):318-30. PubMed ID: 16983183
    [Abstract] [Full Text] [Related]

  • 6. [Ototoxicity in head and neck cancers after radiotherapy and chemoradiotherapy: From primary prevention to tertiary prevention].
    Espenel S, Garcia MA, Guy JB, Vallard A, Ben Mrad M, Langrand-Escure J, El Meddeb Hamrouni A, Trone JC, Xia Y, Rancoule C, Magné N.
    Cancer Radiother; 2017 Feb; 21(1):77-83. PubMed ID: 28189351
    [Abstract] [Full Text] [Related]

  • 7. Relative contributions of radiation and cisplatin-based chemotherapy to sensorineural hearing loss in head-and-neck cancer patients.
    Hitchcock YJ, Tward JD, Szabo A, Bentz BG, Shrieve DC.
    Int J Radiat Oncol Biol Phys; 2009 Mar 01; 73(3):779-88. PubMed ID: 18707819
    [Abstract] [Full Text] [Related]

  • 8. Comprehensive Audiometric Analysis of Hearing Impairment and Tinnitus After Cisplatin-Based Chemotherapy in Survivors of Adult-Onset Cancer.
    Frisina RD, Wheeler HE, Fossa SD, Kerns SL, Fung C, Sesso HD, Monahan PO, Feldman DR, Hamilton R, Vaughn DJ, Beard CJ, Budnick A, Johnson EM, Ardeshir-Rouhani-Fard S, Einhorn LH, Lipshultz SE, Dolan ME, Travis LB.
    J Clin Oncol; 2016 Aug 10; 34(23):2712-20. PubMed ID: 27354478
    [Abstract] [Full Text] [Related]

  • 9. Ototoxicity in locally advanced head and neck cancer patients treated with induction chemotherapy followed by intermediate or high-dose cisplatin-based chemoradiotherapy.
    Driessen CML, Leijendeckers J, Snik A, van der Graaf WTA, de Boer JP, Gelderblom H, Kaanders JHAM, Takes R, van Herpen CML.
    Head Neck; 2019 Feb 10; 41(2):488-494. PubMed ID: 30536479
    [Abstract] [Full Text] [Related]

  • 10. Relative contributions of radiation and cisplatin-based chemotherapy to sensorineural hearing loss in head-and-neck cancer patients.
    Das N, Kaushal D, Patro SK, Pareek P, Dixit A, Soni K, Prakasan Nair N, Choudhury B, Goyal A.
    Acta Otolaryngol; 2021 Sep 10; 141(9):885-893. PubMed ID: 34486907
    [Abstract] [Full Text] [Related]

  • 11. Predicting Hearing Loss After Radiotherapy and Cisplatin Chemotherapy in Patients With Head and Neck Cancer.
    Schuette A, Lander DP, Kallogjeri D, Collopy C, Goddu S, Wildes TM, Daly M, Piccirillo JF.
    JAMA Otolaryngol Head Neck Surg; 2020 Feb 01; 146(2):106-112. PubMed ID: 31750863
    [Abstract] [Full Text] [Related]

  • 12. Risk factors for hearing loss in patients treated with intensity-modulated radiotherapy for head-and-neck tumors.
    Zuur CL, Simis YJ, Lamers EA, Hart AA, Dreschler WA, Balm AJ, Rasch CR.
    Int J Radiat Oncol Biol Phys; 2009 Jun 01; 74(2):490-6. PubMed ID: 19135315
    [Abstract] [Full Text] [Related]

  • 13. Development and validation of a cisplatin dose-ototoxicity model.
    Dille MF, Wilmington D, McMillan GP, Helt W, Fausti SA, Konrad-Martin D.
    J Am Acad Audiol; 2012 Jun 01; 23(7):510-21. PubMed ID: 22992258
    [Abstract] [Full Text] [Related]

  • 14. Ototoxicity in a randomized phase III trial of intra-arterial compared with intravenous cisplatin chemoradiation in patients with locally advanced head and neck cancer.
    Zuur CL, Simis YJ, Lansdaal PE, Hart AA, Schornagel JH, Dreschler WA, Rasch CR, Balm AJ.
    J Clin Oncol; 2007 Aug 20; 25(24):3759-65. PubMed ID: 17704425
    [Abstract] [Full Text] [Related]

  • 15. Sensorineural hearing loss in patients with head and neck cancer after chemoradiotherapy and radiotherapy: a systematic review of the literature.
    Theunissen EA, Bosma SC, Zuur CL, Spijker R, van der Baan S, Dreschler WA, de Boer JP, Balm AJ, Rasch CR.
    Head Neck; 2015 Feb 20; 37(2):281-92. PubMed ID: 24478269
    [Abstract] [Full Text] [Related]

  • 16. Long-term hearing loss after chemoradiation in patients with head and neck cancer.
    Theunissen EA, Zuur CL, Bosma SC, Lopez-Yurda M, Hauptmann M, van der Baan S, de Boer JP, van der Molen L, Rasch CR, Dreschler WA, Balm AJ.
    Laryngoscope; 2014 Dec 20; 124(12):2720-5. PubMed ID: 24964759
    [Abstract] [Full Text] [Related]

  • 17. The Role of Audiometry prior to High-Dose Cisplatin in Patients with Head and Neck Cancer.
    Caballero M, Mackers P, Reig O, Buxo E, Navarrete P, Blanch JL, Grau JJ.
    Oncology; 2017 Dec 20; 93(2):75-82. PubMed ID: 28511189
    [Abstract] [Full Text] [Related]

  • 18. Time course and clinical characterization of cisplatin-induced ototoxicity after treatment for nasopharyngeal carcinoma in a South East Asian population.
    Chan SL, Ng LS, Goh X, Siow CH, Goh HL, Goh BC, Cheo T, Loh KS, Brunham LR.
    Head Neck; 2018 Jul 20; 40(7):1425-1433. PubMed ID: 29451951
    [Abstract] [Full Text] [Related]

  • 19. Impact of radiation technique, radiation fraction dose, and total cisplatin dose on hearing : Retrospective analysis of 29 medulloblastoma patients.
    Scobioala S, Parfitt R, Matulat P, Kittel C, Ebrahimi F, Wolters H, Am Zehnhoff-Dinnesen A, Eich HT.
    Strahlenther Onkol; 2017 Nov 20; 193(11):910-920. PubMed ID: 28887665
    [Abstract] [Full Text] [Related]

  • 20. Dose intensity comparison between weekly and 3-weekly Cisplatin delivered concurrently with radical radiotherapy for head and neck cancer: a retrospective comparison from New Cross Hospital, Wolverhampton, UK.
    Ho KF, Swindell R, Brammer CV.
    Acta Oncol; 2008 Nov 20; 47(8):1513-8. PubMed ID: 18607863
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.